Role of ceramide in morphine hyperalgesia and tolerance

神经酰胺在吗啡痛觉过敏和耐受中的作用

基本信息

  • 批准号:
    7691359
  • 负责人:
  • 金额:
    $ 18.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-30 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Opiate/narcotic analgesics, typified by morphine sulfate, are the most effective analgesics for treating acute and chronic severe pain, but their clinical utility is often hampered by the development of analgesic tolerance and painful hypersensitivity to both innocuous and noxious stimuli. The mechanisms by which chronic opiate exposure induce hyperalgesia and antinociceptive tolerance are unclear but neuroimmune activation, cellular apoptosis and oxidative/nitrative stress in the spinal cord have been proposed, Ceramide is a sphingolipid signaling molecule with powerful proapoptotic and proinflammatory properties and may also contribute to oxidative/nitrative stress. Ceramide is generated from de novo synthesis coordinated by serine palmitosyltransferase and ceramide synthase and/or by enzymatic hydrolysis of sphingomyelin by sphingomyelinases (SMases). Using a well established murine model, our preliminary experiments revealed that repeated administration of morphine increased the levels of ceramide in the dorsal horn of the lumbar segment of the spinal cord and that its inhibition by fumonisin B1, an inhibitor of ceramide synthase, attenuated the development of antinociceptive tolerance. These events were associated with inhibition of apoptosis and oxidative/nitrative stress in dorsal horn tissues. Furthermore, inhibition of ceramide synthesis by D609 and myriocin, inhibitors of SMAse/sphingomyelin synthase and serine palmitoyltransferase respectively blocked antinociceptive tolerance. Together, these findings support the central thesis of this exploratory proposal: increased formation of ceramide in the spinal cord is an important pathway in the development of morphine-induced hyperalgesia and antinociceptive tolerance. To address this novel hypothesis, we propose a comprehensive experimental strategy employing molecular, bio-analytical, biochemical, pharmacological and genetic approaches. Two Specific Aims will test our hypothesis. In Specific Aim 1, we will demonstrate by pharmacologic and genetic approaches that inhibition of the increased formation of ceramide blocks the development of morphine- induced hyperalgesia and antinociceptive tolerance thus identifying the predominant enzymatic pathway responsible for its biosynthesis. In Specific Aim 2, we will elucidate the molecular and biochemical mechanisms whereby ceramide modulates hyperalgesia and antinociceptive tolerance. Specifically, we will determine ceramide's effects on three biochemical pathways within spinal tissue: (a) neuroimmune activation, (b) oxidative/nitrative stress and (c) apoptosis. Successful validation of our hypothesis will define for the first time the important role of ceramide in morphine-induced hyperalgesia and antinociceptive tolerance providing the scientific foundation towards the development of inhibitors of ceramide biosynthesis as adjunct to opiates for the management of chronic pain, in particular for those patients who require long-term opioid treatment for pain relief. PUBLIC HEALTH RELEVANCE Opioid drugs such as morphine are the most effective analgesics for treating severe chronic pain, but their pain-relieving action is often diminished during chronic administration, necessitating dose escalation that reduces quality of life for the patient. Our studies will determine for the first time that inhibition of ceramide biosynthesis, with novel agents, restores the pain-relieving action of morphine. The broader implications of our findings may open a new frontier in chronic pain management thus alleviating the socioeconomic consequences it causes.
描述(申请人提供):以硫酸吗啡为代表的阿片类/麻醉性镇痛药是治疗急性和慢性剧烈疼痛最有效的镇痛药,但其临床应用常常因镇痛耐受性的发展以及对无害和有害刺激的疼痛过敏而受到阻碍。慢性阿片类药物暴露引起痛觉过敏和抗伤害耐受的机制尚不清楚,但已提出神经免疫激活、细胞凋亡和脊髓氧化/硝化应激。神经酰胺是一种鞘脂信号分子,具有强大的促凋亡和促炎特性,也可能导致氧化/硝化应激。神经酰胺是由丝氨酸棕榈糖基转移酶和神经酰胺合酶协调的从头合成和/或鞘磷脂酶 (SMase) 酶促水解鞘磷脂产生的。使用完善的小鼠模型,我们的初步实验表明,重复施用吗啡会增加脊髓腰段背角的神经酰胺水平,并且神经酰胺合酶抑制剂伏马菌素 B1 的抑制作用会减弱镇痛耐受的发展。这些事件与背角组织中细胞凋亡和氧化/硝化应激的抑制有关。此外,D609 和多球菌素对神经酰胺合成的抑制、SMAse/鞘磷脂合酶和丝氨酸棕榈酰转移酶的抑制剂分别阻断了镇痛耐受。总之,这些发现支持了这一探索性提议的中心论点:脊髓中神经酰胺形成的增加是吗啡引起的痛觉过敏和镇痛耐受发生的重要途径。为了解决这一新假设,我们提出了一种采用分子、生物分析、生物化学、药理学和遗传学方法的综合实验策略。两个具体目标将检验我们的假设。在具体目标 1 中,我们将通过药理学和遗传学方法证明,抑制神经酰胺形成的增加可以阻止吗啡诱导的痛觉过敏和镇痛耐受的发展,从而确定负责其生物合成的主要酶途径。在具体目标 2 中,我们将阐明神经酰胺调节痛觉过敏和镇痛耐受的分子和生化机制。具体来说,我们将确定神经酰胺对脊柱组织内三种生化途径的影响:(a)神经免疫激活,(b)氧化/硝化应激和(c)细胞凋亡。我们的假设的成功验证将首次明确神经酰胺在吗啡引起的痛觉过敏和抗伤害耐受中的重要作用,为开发神经酰胺生物合成抑制剂作为阿片类药物的辅助治疗慢性疼痛提供科学基础,特别是对于那些需要长期阿片类药物治疗缓解疼痛的患者。公共卫生相关性吗啡等阿片类药物是治疗严重慢性疼痛最有效的镇痛药,但在长期给药过程中,其止痛作用往往会减弱,需要增加剂量,从而降低患者的生活质量。我们的研究将首次确定,用新型药物抑制神经酰胺生物合成可以恢复吗啡的止痛作用。我们的研究结果具有更广泛的影响,可能会开辟慢性疼痛管理的新领域,从而减轻其造成的社会经济后果。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Peroxynitrite and opiate antinociceptive tolerance: a painful reality.
Spinal NADPH oxidase is a source of superoxide in the development of morphine-induced hyperalgesia and antinociceptive tolerance.
脊髓 NADPH 氧化酶是吗啡引起的痛觉过敏和镇痛耐受中超氧化物的来源。
  • DOI:
    10.1016/j.neulet.2010.07.013
  • 发表时间:
    2010-10-11
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Doyle, Tim;Bryant, Leesa;Muscoli, Carolina;Cuzzocrea, Salvatore;Esposito, Emanuela;Chen, Zhoumou;Salvemini, Daniela
  • 通讯作者:
    Salvemini, Daniela
Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids.
Targeting peroxynitrite driven nitroxidative stress with synzymes: A novel therapeutic approach in chronic pain management.
用合酶靶向过氧亚硝酸盐驱动的硝基氧化应激:慢性疼痛管理的一种新治疗方法。
  • DOI:
    10.1016/j.lfs.2009.06.011
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Salvemini,Daniela;Neumann,William
  • 通讯作者:
    Neumann,William
NMDA-receptor activation and nitroxidative regulation of the glutamatergic pathway during nociceptive processing.
  • DOI:
    10.1016/j.pain.2010.01.015
  • 发表时间:
    2010-04
  • 期刊:
  • 影响因子:
    7.4
  • 作者:
    Chen Z;Muscoli C;Doyle T;Bryant L;Cuzzocrea S;Mollace V;Mastroianni R;Masini E;Salvemini D
  • 通讯作者:
    Salvemini D
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DANIELA SALVEMINI其他文献

DANIELA SALVEMINI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DANIELA SALVEMINI', 18)}}的其他基金

Isolation of GPR160 for biochemical analysis of the activation mechanism and development of a high throughput screening assay to identify small molecule inhibitors
分离 GPR160,用于激活机制的生化分析,并开发高通量筛选方法来鉴定小分子抑制剂
  • 批准号:
    10176852
  • 财政年份:
    2020
  • 资助金额:
    $ 18.06万
  • 项目类别:
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicity
A3AR 激动剂作为减轻化疗引起的神经毒性的新方法
  • 批准号:
    10460227
  • 财政年份:
    2019
  • 资助金额:
    $ 18.06万
  • 项目类别:
Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponses
阿片类药物诱导的 S1P/S1PR1 轴激活在神经炎症反应中的作用
  • 批准号:
    9751234
  • 财政年份:
    2018
  • 资助金额:
    $ 18.06万
  • 项目类别:
Preserving opioid analgesia using a novel adenosinergic approach
使用新型腺苷能方法保持阿片类镇痛作用
  • 批准号:
    8974700
  • 财政年份:
    2015
  • 资助金额:
    $ 18.06万
  • 项目类别:
Preserving opioid analgesia using a novel adenosinergic approach
使用新型腺苷能方法保持阿片类镇痛作用
  • 批准号:
    9095273
  • 财政年份:
    2015
  • 资助金额:
    $ 18.06万
  • 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
  • 批准号:
    9042993
  • 财政年份:
    2013
  • 资助金额:
    $ 18.06万
  • 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
  • 批准号:
    8501971
  • 财政年份:
    2013
  • 资助金额:
    $ 18.06万
  • 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
  • 批准号:
    9278122
  • 财政年份:
    2013
  • 资助金额:
    $ 18.06万
  • 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
  • 批准号:
    8634753
  • 财政年份:
    2013
  • 资助金额:
    $ 18.06万
  • 项目类别:
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
A3AR 激动剂可预防化疗引起的疼痛性周围神经病变
  • 批准号:
    8830342
  • 财政年份:
    2013
  • 资助金额:
    $ 18.06万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了